SCHEMBL6490296

SCHEMBL6490296

CC(C)(N)CCOc1ccc(C(=O)OCc2ccccc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.55
TDP1 Q9NUW8 2/20 0.55
SLC6A2 P23975 1/20 0.55
SLC6A3 Q01959 1/20 0.55
LMNA P02545 1/20 0.55
MAPT P10636 4/20 0.52
ALDH1A1 P00352 2/20 0.52
HPGD P15428 1/20 0.52
ADRB2 P07550 1/20 0.52
ADRB1 P08588 1/20 0.52
ADRB3 P13945 1/20 0.52
RAB9A P51151 2/20 0.49
MAOB P27338 1/20 0.49
PARP10 Q53GL7 1/20 0.49
L3MBTL1 Q9Y468 2/20 0.48
GAA P10253 1/20 0.48
NR4A1 P22736 1/20 0.48
NR4A2 P43354 1/20 0.48
NR4A3 Q92570 1/20 0.48
PPARA Q07869 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6488197 0.87 KMT2A (0.58) KMT2ATDP1SLC6A2SLC6A3LMNA
SCHEMBL20082424 0.86 MAOB (0.52) KMT2ATDP1SLC6A2SLC6A3LMNA
SCHEMBL51012 0.85 KMT2A (0.71) KMT2ATDP1SLC6A2SLC6A3LMNA
SCHEMBL850700 0.84 KMT2A (0.58) KMT2ATDP1SLC6A2SLC6A3LMNA
SCHEMBL6488614 0.83 ADRB2 (0.54) KMT2ATDP1SLC6A2SLC6A3LMNA
SCHEMBL20830910 0.82 TSHR (0.65) KMT2ATDP1SLC6A2SLC6A3LMNA
SCHEMBL13481158 0.82 KMT2A (0.63) KMT2ATDP1SLC6A2SLC6A3LMNA
SCHEMBL6538648 0.81 KMT2A (0.61) KMT2ATDP1SLC6A2SLC6A3LMNA
SCHEMBL20830913 0.81 MAPT (0.61) KMT2ATDP1SLC6A2SLC6A3LMNA
SCHEMBL8673498 0.81 KMT2A (0.65) KMT2ATDP1SLC6A2SLC6A3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6867299-B2 Inosine monophosphate dehydrogenase (IMPDH); use as immunosuppressants, anticancer agents and antiviral agents HOFFMANN-LA ROCHE INC. (US) 2005-03-15 US disclosed
US-20020052513-A1 Oxamide IMPDH inhibitors HOFFMANN-LA ROCHE INC. 2002-05-02 US disclosed
EP-1127883-A2 Oxamides as IMPDH inhibitors F. HOFFMANN-LA ROCHE AG (CH) 2001-08-29 EP disclosed
CN-1310179-A Oxamide being as IMPDH inhibitor HOFFMANN LA ROCHE (CH) 2001-08-29 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052513-A1 Oxamide IMPDH inhibitors IMPDH1, IMPDH2, IMPA1 KMT2A 3733/4885TDP1 557/4885SLC6A2 1338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.